Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
CC transcript
Quarterly results
Director departure
Pharmasset Inc (VRUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/16/2011 PRN Pharmasset Announces Intent to Amend QUANTUM Trial
11/21/2011 PRN The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Pharmasset, Inc. in Connection with the Sale of the Company to Gilead Sciences, Inc.
11/13/2011 PRN Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11/04/2011 PRN Pharmasset to Webcast an Investor Event from the AASLD Meeting
09/16/2011 PRN Pharmasset to Present at Two Upcoming Conferences
09/13/2011 PRN Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
09/06/2011 PRN Pharmasset to Present at Two Upcoming Conferences
09/06/2011 PRN Pharmasset Announces 91% SVR12 From the PROTON Trial in Subjects With Hepatitis C Genotype 1
08/24/2011 PRN PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
07/20/2011 PRN Pharmasset Announces Final SVR Data from PROTON trial with PSI-7977 in Subjects Infected with Hepatitis C Infection Genotype 2 or 3
07/06/2011 PRN Pharmasset Enters into a Clinical Collaboration Agreement with Tibotec Pharmaceuticals for a Combination Study in Patients Chronically Infected with Hepatitis C
06/08/2011 PRN Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
06/05/2011 PRN Pharmasset to Present at Two Upcoming Conferences
05/26/2011 PRN All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
05/14/2011 PRN Pharmasset to Present at Two Upcoming Conferences
04/28/2011 PRN Pharmasset to Present at Two Upcoming Investor Conferences
04/25/2011 PRN Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
03/30/2011 PRN Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
03/28/2011 PRN Pharmasset to Webcast an Investor Event From the EASL Meeting
02/25/2011 PRN Pharmasset to Present at Three Upcoming Investor Conferences
02/14/2011 PRN Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
05/13/2010 PRN Pharmasset Prices Public Offering of Common Stock
04/30/2010 PRN Pharmasset to Present at the Bank of America Merrill Lynch Health Care Conference
04/15/2010 PRN Pharmasset Announces Interim Data from an Ongoing 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection
04/13/2010 PRN Pharmasset to Present New Data on RG7128 and PSI-7977 at the EASL Conference
04/08/2010 PRN Pharmasset Initiates First Time in Human Study of PSI-938 for the Treatment of Hepatitis C

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy